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Dr Paul H. Schipper (Portland, Ore). I would like to know
more about how I can use this data set clinically, so I have 2 ques-
tions for you. The first question has to dowith the 42-month or 3.5-
year median interval between the first and second surgery. This is
a retrospective case series, an inherent problem of which is that
you are not the first person to screen the data. The data is in fact
first screened by the surgeon who made the decision to operate
or not to operate on this person a second time. I think the surgeons
at the Mayo Clinic probably had a couple things in mind as they
were making this decision. One is the Martini and Melamed crite-
ria of a 2-year interval to consider something a new primary versus
a recurrence. The second is that statistically most recurrences hap-
pen in that first 2 years, and the final is that at least I feel more com-
fortable with a trial of time. I can say to myself, okay, it has been 2690 The Journal of Thoracic and Cardiovascular Surgyears and this is the only disease we see—let’s apply this local
therapy of surgery.
So, based on your data can you make any suggestions as to what
I should do with a 1.5-cm lesion showing up 6 months or 1 year
from the initial lesion? Do you think that this 3.5-year period is
selecting for slower-growing, biologically less active tumors?
Dr Hamaji. Although Martini and Melamed in their original
1975 publication proposed that, for tumors of the same histology,
a DFI of at least 2 years was required to be considered a metachro-
nous lung cancer, we specifically eliminated the requirement of
a DFI of at least 2 years when selecting patients for this study to
be able to validate if that criteria is associated with survival. We
did not find any association of DFI with survival, so if the patient
is medically fit and can tolerate additional surgery and you believe
that the second lesion is an MSPLC and not local recurrence or
a metastasis, we would recommend surgical resection.
Dr Schipper.And that 3.5-year period? Maybe the patients that
you are presenting to us have tumors that are less biologically
active? Or in other words, these patients made it through that
3.5-year period. Maybe there is another subset of patients who
did not and the surgeons at Mayo said to themselves, ‘‘Your tumor
showed up 6 months after an operation, this is an aggressive tumor,
maybe I should not apply local therapy, maybe you would be better
served with chemotherapy or radiation therapy.’’ Those patients,
therefore, did not make it into the study.
Dr Hamaji. We analyzed the DFIs of 2 years, 3 years, and 5
years, and compared patients with DFIs<2 years and patients
with DFIs>2 years, and we did not find a significant difference
in survival. We did the same analysis for the 3 years and 5 years
patients, so we did not use the time range for patient selection.
Our recommendation is unless the patient has ground-glass opacity
we will be very aggressive for surgical management of the lung
nodule.
Dr Schipper. So anywhere from 2 to 5 years after your first
operation is okay,<2 years is still questionable? Would you agree
with that?
Let me ask my second question. You talk about surveillance im-
aging and your conclusion is that you recommend surveillance im-
aging. One of the things you point out is that in your analysis of the
patients who had surveillance versus those that did not, there was
no difference in survival and that in a significant group of your pa-
tients the tumor was found by chance. Meanwhile, 100% of the pa-
tients you operated on were asymptomatic. Although I agree with
the need for surveillance, I am curious as to how you came to that
conclusion using your data.
Dr Hamaji. Before our analysis we expected that chest com-
puted tomography (CT) surveillance would be superior to x-ray
surveillance but actually we failed to show chest CT’s advantage.
The reason, we think, is because of our small number of patients.
Theoretically chest CT is superior in picking up a smaller nodule,
which we showed is a significant factor in better survival after
a second lung cancer, so we recommend chest CT for surveillance.
Dr Frederic Grannis (Duarte, Calif). John Benfield, a former
president of this organization, many years ago showed an enor-
mous risk of second lung cancer and also head and neck cancer fol-
lowing treatment of a tobacco-related cancer. Based on that, we
have been doing annual CT scans in all of our survivors for almost
30 years now. Jeff Lemont published that data and showed that theery c March 2013
Hamaji et al General Thoracic Surgerysurveillance benefit of a CT scan is very minor, but the screening
benefit is enormous. We reported 85% detection of second lung
cancers in stage 1A and 70% alive at 4 years.
Now to the question. The recent American Association for Tho-
racic Surgery meeting gave a guideline recommendation that we
should be screening all patients with a first lung cancer and I agree
with that, but we cannot tell from your data the characteristics of
the patients who had a second lung cancer but were not operatedThe Journal of Thoracic and Ca
T
Son. Can you tell us how many such patients there were and what
were the survival and screening characteristics of the other group
of patients who were not operated on?
Dr Hamaji. We only analyzed patients who had second lung
cancer surgery and we did not look into patients who were man-
aged medically and we did not compare the 2 patient groups, so
I do not have any information on the patients with MSPLC who
did not undergo surgical treatment.rdiovascular Surgery c Volume 145, Number 3 691
G
